Product Name: BAP1 Antibody
Species Reactivity: Human, Mouse
Tested Applications: IHC-P, WB
Applications: For WB starting dilution is: 1:1000For IHC-P starting dilution is: 1:50~100
User Note: Optimal dilutions for each application to be determined by the researcher.
Predicted Molecular Weight: 80 kDa
Immunogen: This BAP1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 36-66 amino acids from the N-terminal region of human BAP1.
Host Species: Rabbit
Purification: This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis
Physical State: Liquid
CAS NO.: 186139-09-3
Product: MSI-1436
Buffer: Supplied in PBS with 0.09% (W/V) sodium azide.
Concentration: 2 mg/ml
Storage Conditions: Store at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Clonality: Polyclonal
Conjugate: Unconjugated
Alternate Names: Ubiquitin carboxyl-terminal hydrolase BAP1, BRCA1-associated protein 1, Cerebral protein 6, BAP1, KIAA0272
Accession NO.: Q92560
Protein Ino: 68565074
Official Symbol: BAP1
Geneid: 8314
Background: BRCA1-associated protein-1, or BAP1 interacts with the RING finger domain of BRCA1. The N-terminal 240 amino acids of the predicted 729-amino acid human protein show homology to ubiquitin C-terminal hydrolases (UCHs), thiol proteases that catalyze proteolytic processing of ubiquitin. In addition, BAP1 contains an acidic region, a highly charged C-terminal region, and 2 putative nuclear localization signals.. BAP1 and BRCA1 associate in vivo and have overlapping subnuclear localization patterns.1 BAP1 enhances BRCA1-mediated inhibition of breast cancer cell growth. Northern blot analysis indicates that BAP1 is expressed as a 4-kb mRNA in all human tissues tested, with A 4.8-kb transcript expressed exclusively in testis. Northern blot analysis and in situ hybridization reveal that BAP1 and BRCA1 are coexpressed during murine breast development and remodeling. The BAP1 gene has been mapped to 3p21.3, a region of loss of heterozygosity for breast cancer as well as frequently deleted in lung carcinomas.1 Intragenic homozygous rearrangements and deletions of BAP1 appear in lung carcinoma cell lines. It has been postulated that BAP1 is a tumor suppressor gene that functions in the BRCA1 growth control pathway.1
PubMed ID:http://aac.asm.org/content/53/10/4495.abstract
